Emergent BioSolutions第四季度调整后每股收益$0.05,超出预期$(0.49),销售额$194.70M不及预期$254.67M

财报速递03-04
Emergent BioSolutions(纽约证券交易所代码:EBS)报告的季度每股收益为$0.05,比分析师预期的$(0.49)高出110.2%。 这比去年同期每股亏损$(0.77)增加了106.49%。公司报告的季度销售额为$194.70M,不及分析师预期的$254.67M,低23.55%。 这比去年同期的销售额$276.60M减少了29.61%。

以上内容来自Benzinga Earnings专栏,原文如下:

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.49) by 110.2 percent. This is a 106.49 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $194.70 million which missed the analyst consensus estimate of $254.67 million by 23.55 percent. This is a 29.61 percent decrease over sales of $276.60 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法